SBC Medical Group (NASDAQ:SBC – Get Free Report) posted its earnings results on Friday. The company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.03, FiscalAI reports. SBC Medical Group had a net margin of 27.99% and a return on equity of 18.47%. The firm had revenue of $58.58 million during the quarter, compared to analyst estimates of $48.90 million.
Here are the key takeaways from SBC Medical Group’s conference call:
- Q3 growth and margins accelerated: Revenue rose 35% year over year to $59 million, while operating income and Adjusted EBITDA each increased 66%; Adjusted EBITDA margin expanded 9 percentage points to 47%. Management attributed growth partly to revised service fees, equipment-related rental revenue, and the newly consolidated Waqoo segment.
- Existing clinics and the network both grew: Nine-month same-clinic revenue increased 7%, with visits up 9% and average spend per visit up 4%; the network reached 293 locations. Management expects clinic expansion to continue and cited plans to grow general-medicine services and pursue acquisitions.
- AI and longevity are longer-term growth opportunities: SBC is developing diagnostic tests and AI tools for clinic operations and personalized care, with longevity services targeted to contribute meaningfully from around 2028. Management expects AI and network scale to support further margin improvement, but did not quantify the impact or timing.
- No additional share buybacks are planned for now: Despite cash exceeding $200 million, management said it will prioritize acquisitions and new clinic openings, while continuing to focus on improving liquidity.
- Liquidity has improved, while governance changes remain in progress: October average daily trading value was about $1 million, 4.1 times July’s level, and the shareholder base grew 1.6 times. Management said it is advancing the selection of independent directors, but gave no appointment date.
SBC Medical Group Trading Up 37.6%
SBC stock traded up $2.01 during midday trading on Friday, reaching $7.35. 1,710,244 shares of the company traded hands, compared to its average volume of 190,995. SBC Medical Group has a 52-week low of $2.78 and a 52-week high of $7.39. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.27 and a current ratio of 3.31. The business has a 50 day moving average of $5.13 and a 200-day moving average of $3.98. The firm has a market capitalization of $755.95 million, a price-to-earnings ratio of 15.64, a P/E/G ratio of 2.40 and a beta of 0.52.
Latest SBC Medical Group News
Investors following SBC have been watching these news items:
- Positive Sentiment: Third-quarter revenue rose 35% to $58.6 million, ahead of the $48.9 million analyst estimate. EPS of $0.15 also beat the $0.12 consensus. Net income attributable to SBC increased 22% to $15.7 million, while adjusted EBITDA rose 66% year over year. SBC Medical Group Holdings Reports Third Quarter 2026 Financial Results
- Positive Sentiment: Growth was supported by higher management-services revenue, service-fee revisions and the consolidation of Waqoo. The clinic network expanded to 293 locations, up 36 from a year earlier; the company reported $198.4 million in cash at quarter-end. SBC Medical Q3 Revenue Rises 35% to $58.6 Million
- Positive Sentiment: SBC announced a capital and business alliance with NeuroBrain Dynamics, a generative-AI company, with the stated goal of using medical AI to improve clinic profitability. The financial impact and rollout details were not disclosed. SBC Medical Announces Capital and Business Alliance with NeuroBrain Dynamics
Wall Street Analysts Forecast Growth
SBC has been the subject of several research reports. Weiss Ratings upgraded shares of SBC Medical Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, October 9th. Wall Street Zen cut shares of SBC Medical Group from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Finally, BTIG Research restated a “buy” rating and issued a $8.00 target price on shares of SBC Medical Group in a report on Thursday, August 13th. One investment analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $8.00.
View Our Latest Analysis on SBC Medical Group
SBC Medical Group Company Profile
SBC Medical Group Holdings provides management and support services to medical institutions, with a focus on clinics offering aesthetic medicine. Its services include support for clinic operations, marketing, staff training, procurement and customer service, allowing affiliated medical providers to focus on patient care. The group is associated with the Shonan Beauty Clinic brand and a broader network of clinics offering services such as cosmetic surgery and dermatology. Its business is centered primarily in Japan, where it supports the operations and growth of affiliated medical institutions.
Read More
- Five stocks we like better than SBC Medical Group
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for SBC Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SBC Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.
